Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
How Has the Dysautonomia (Autonomic Dysfunction) Market Growth Performance Trended Historically, And What Lies Ahead?
In recent times, the market size for dysautonomia (autonomic dysfunction) has seen a swift growth. The market, which stood at $2.62 billion in 2024, is projected to rise to $2.92 billion in 2025, signifying a compound annual growth rate (CAGR) of 11.8%. This growth during the historic period is credited to several factors such as the increased occurrences of autonomic disorders, heightened awareness about dysautonomia, growing healthcare spending, expanding research into neurodegenerative diseases, and escalating government backing for rare diseases.
The market for dysautonomia (autonomic dysfunction) is anticipated to witness a significant surge in the upcoming years. The market is projected to balloon to $4.53 billion by 2029, boasting an 11.5% compound annual growth rate (CAGR). This expansion during the forecast period can be credited to factors such as an increase in the uptake of personalized medicine, a surge in clinical trials for innovative treatments, escalated government support for research on rare diseases, the broadening of telemedicine and remote monitoring solutions, and the growing availability of orphan drugs. Integral trends during the forecast period encompass the incorporation of artificial intelligence in the diagnosis, the generation of targeted therapies, the use of wearable devices for autonomic monitoring, progress in gene therapies, and innovations in patient-centric treatments.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21177&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Dysautonomia (Autonomic Dysfunction) Market?
The escalating frequency of long-term illnesses is anticipated to spur the expansion of the dysautonomia (autonomic dysfunction) market. Chronic illnesses, which last for three months or more, have seen a rise due to factors like the greater occurrence of multimorbidity – the simultaneous diagnosis of multiple chronic ailments. Dysautonomia has a significant impact on chronic diseases by interfering with the body’s capacity to manage vital functions such as heart rate, blood pressure, and digestion, often intensifying symptoms and making treatment more complex. For example, data from the National Health Service in October 2023 revealed that Type 1 diabetes prevalence in England grew from 261,710 cases in 2020-21 to 270,935 cases in 2021-22, marking a 3.5% year-over-year increase. Thus, the escalating prevalence of long-term illnesses is spurring the dysautonomia market’s growth. The ascend in autoimmune and neurological disorders is also anticipated to boost the dysautonomia (autonomic dysfunction) market’s expansion. These disorders, in which the immune system erroneously attacks the nervous system, can cause inflammation, damage, and dysfunction in the brain, spinal cord, or peripheral nerves. The upswing in these conditions is attributed to factors like genetic predisposition, environmental catalysts, lifestyle modifications, infections, and enhanced diagnostic capabilities. Dysautonomia is a key marker of underlying autoimmune and neurological disorders, helping medical practitioners identify, track, and manage disease progression while devising tailored treatment strategies. For example, in July 2023, Public Health Scotland reported that newly diagnosed multiple sclerosis patients increased to 87.2% in 2022, up from 85.7% in the previous two years, adding 491 new cases and bringing the total to 6,359. Consequently, this increase in autoimmune and neurological disorders is expected to drive the dysautonomia market’s growth.
Which Key Market Segments Comprise the Dysautonomia (Autonomic Dysfunction) Market and Drive Its Revenue Growth?
The dysautonomia (autonomic dysfunction) market covered in this report is segmented –
1) By Type: Neurogenic Orthostatic Hypotension (NOH), Postural Orthostatic Tachycardia Syndrome (POTS), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Other Types
2) By Tests: Cardiovagal and Vasomotor Function Tests, Thermoregulatory Sweat Test (TST), Sympathetic Skin Response (SSR), Quantitative Sudomotor Axon Reflex Test, Other Tests
3) By Treatment: Physical Therapy, Exercise Therapy, Counseling, Other Treatments
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Clinics, Diagnostic Centers, Research Institutes
Subsegments:
1) By Neurogenic Orthostatic Hypotension (NOH): Primary NOH, Secondary NOH (due to Parkinson’s Disease, Diabetes, etc.), Pharmacological Management of NOH, Non-Pharmacological Interventions
2) By Postural Orthostatic Tachycardia Syndrome (POTS): Hyperadrenergic POTS, Hypovolemic POTS, Neuropathic POTS, Autoimmune POTS, Treatment With Beta-Blockers, Fludrocortisone, And Salt Supplements
3) By Multiple System Atrophy (MSA): MSA-P (Parkinsonism), MSA-C (Cerebellar), MSA-A (Autonomic), Disease-Modifying and Symptomatic Treatment
4) By Pure Autonomic Failure (PAF): Idiopathic PAF, Secondary PAF (due to neurodegenerative diseases), Autonomic Supportive Treatments
5) By Other Types: Familial Dysautonomia (FD), Diabetic Autonomic Neuropathy, Horner’s Syndrome, Autoimmune Autonomic Ganglionopathy, Chronic Fatigue Syndrome-related Dysautonomia
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21177&type=smp
Which Areas Are Leading Regions in the Dysautonomia (Autonomic Dysfunction) Market Expansion Across the Globe?
North America was the largest region in the dysautonomia (autonomic dysfunction) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dysautonomia (autonomic dysfunction) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in theDysautonomia (Autonomic Dysfunction) Market Over the Coming Years?
Leading enterprises in the dysautonomia (autonomic dysfunction) market are placing emphasis on pioneering advancements in gene therapy, such as recombinant adeno-associated virus, to augment the conveyance of healing genes to specific cells. This approach aims to heighten treatment results for patients grappling with varied forms of dysautonomia. Recombinant adeno-associated virus (rAAV) is an altered virus employed in gene therapy for the transportation of genetic matter into cells without inducing disease. As an example, in January 2025, Tikun Therapeutics Inc., an American biotechnology corporation, acquired approval for Orphan Drug and Rare Pediatric Disease Designations from the Food and Drug Administration (FDA) for rAAV2-U1a-hELP1 (a gene therapy for optic neuropathy in familial dysautonomia) and BPN-36964 (a small molecule splicing modulator for systemic FD treatment). These pioneering therapies aim to deal with the basic genetic origins of FD, offering potential enduring advantages over symptomatic management.
View the full report here:
How Is the Dysautonomia (Autonomic Dysfunction) Market Conceptually Defined?
Dysautonomia, or autonomic dysfunction, refers to a condition where the autonomic nervous system (ANS) does not function properly, affecting involuntary bodily functions such as heart rate, blood pressure, digestion, and temperature regulation. It can result from various causes, including genetic factors, injuries, or underlying health conditions, leading to symptoms like dizziness, fainting, and irregular heartbeat.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21177
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model